Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT06127290Recruiting
HIV treatment study for people in Eastern Europe and Russia
This study looks at how well newer HIV medicines work in people starting treatment for the first time in Eastern Europe and Russia. It also checks for drug resistance to find better treatment strategies.
CologneAges 18 years+ - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT07181486RecruitingPhase 1
Safety study of a vaginal gel for healthy women
This trial tests a gel placed in the vagina to see if it is safe. Healthy women with regular periods who have a steady partner may join.
San Francisco, CaliforniaAges 18–45 - NCT06843902RecruitingPhase 2
Improving heart blood flow in women with HIV and diabetes or kidney problems
This trial tests a new approach to improve blood flow in the hearts of women with HIV who also have diabetes or kidney problems. It might help prevent heart disease in this population.
Boston, MassachusettsAges 45–75 - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT06762054Recruiting
Better management for dolutegravir-resistant HIV
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
KisumuAges 1 year+ - NCT06747507RecruitingPhase 3
Ndovu study: best HIV treatment for drug resistance
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
KisumuAges 3 years+ - NCT06691321Recruiting
Caspofungin for Pneumocystis Pneumonia in HIV patients
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Mexico City, TlalpanAges 18–60 - NCT06507059RecruitingPhase 3
Injectable HIV treatment trial for people with unsuppressed virus
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
KeelungAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT05129345Recruiting
HIV care program for heart health goals in the Southeast US
This trial tests an approach to help people living with HIV reach heart- and metabolism-related health goals, such as blood pressure, cholesterol, and blood sugar. It involves clinics and community partners and may offer education, support, and care coordination to remove barriers to treatment.
Charlotte, North CarolinaAges 18 years+ - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT04892654RecruitingPhase 3
Doravirine plus dolutegravir switch for people with HIV
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
LondonAges 18 years+ - NCT07616739RecruitingPhase 4
Dolutegravir and Lamivudine for Pregnant Women with HIV
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Ciudad Autónoma de Buenos Aires, Buenos AiresAges 15 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT03449706Recruiting
Tracking immune changes in early HIV
This study looks closely at how your immune system and HIV infection markers change right after a new HIV diagnosis. It may help doctors understand the earliest stages of HIV and improve how infections are measured and followed over time.
Ghent, Oost-VlaanderenAges 18–65 - NCT07481175RecruitingPhase 1
Testing a drug to reduce hidden HIV early after treatment start
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
AarhusAges 18–70 - NCT00796146Recruiting
Study people newly infected with HIV to learn early changes
This study enrolls adults with a very recent (“acute”) HIV infection to follow them over time and better understand what happens early after infection. Your participation may help researchers improve how acute HIV is detected and managed.
Bangkok, BangkokAges 18 years+ - NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04653610Recruiting
Study immune signals in untreated HIV using extra samples
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Ghent, Oost-VlaanderenAges 18–65 - NCT06967753RecruitingPhase 4
Switching to a two-drug HIV regimen for transgender women
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Buenos Aires, Buenos Aires F.D.Ages 18 years+
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 86 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.